Cargando…

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens

BACKGROUND: Cefiderocol is a siderophore cephalosporin with potent antibacterial activity against a broad range of Gram-negative pathogens. Microorganisms forming biofilm, e.g., cUTI, utilize bacterial siderophores to access free iron. A siderophore antibiotic may have unique antimicrobial propertie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pybus, Christine A, Greenberg, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811222/ http://dx.doi.org/10.1093/ofid/ofz360.787

Ejemplares similares

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens
por: Klinker, Kenneth, et al.
Publicado: (2018)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK
por: Wareham, D., et al.
Publicado: (2022)

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices
por: Bodro, Marta, et al.
Publicado: (2021)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections
por: Teran, Nicholas S, et al.
Publicado: (2023)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2021)

640. A Retrospective Assessment of the Effects of Cefiderocol in Patients with Multidrug-resistant Gram-negative Bacterial Infections
por: Sajib, Monirul I, et al.
Publicado: (2022)

2118. Comparative Analysis of Cefiderocol Mono- and Combination Therapy for Multi-Drug Resistant Gram-negative Infections
por: Ghali, Amer El, et al.
Publicado: (2023)

719. The Respiratory Pathogen Panel and Antibiotic Utilization in the Emergency Department
por: Taupin, Daniel, et al.
Publicado: (2018)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
por: Thomson, Kenneth S., et al.
Publicado: (2019)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
por: Oueslati, Saoussen, et al.
Publicado: (2022)

660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model
por: Kidd, James M, et al.
Publicado: (2019)

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2018)

P24 Cefiderocol activity against a multidrug-resistant (MDR) strain of Pseudomonas aeruginosa: a case report
por: Lim,, Felicia H., et al.
Publicado: (2022)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Poster Sessions 555 - 719
Publicado: (2003)

1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
por: Kung, Frank H, et al.
Publicado: (2022)

144. Gram Negative Bacteria with Increased Minimal Inhibitory Concentration for Cefiderocol among Pediatric Patients in a Northern Italy Hospital.
por: Russo, Chiara, et al.
Publicado: (2022)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

2753. Real-World Use of Cefiderocol Treating Non-COVID Patients with Confirmed Gram-Negative Infections in US Hospitals During January 2020-June 2022
por: Cai, Bin, et al.
Publicado: (2023)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019)

1671. Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

292. Phosphorodiamidate Morpholino Oligomers Targeting acpP Reduce the Biofilm Burden in Burkholderia cepacia Complex
por: Mendez, Antonio R, et al.
Publicado: (2023)

1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin
por: Kinoshita, David PatersonDavid PatersonMasahiro, et al.
Publicado: (2020)

2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean, et al.
Publicado: (2018)

2745. In-Vitro Activity of Cefiderocol Against Multidrug Resistant Strains of P. aeruginosa DTR, A. baumannii complex DTR, A. xylosoxidans MDR, S. maltophilia MDR & B. cepacia complex, by Iron-Depleted Broth Microdilution
por: Alexander, Jose, et al.
Publicado: (2023)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aavrcvbcehitqr1skf8kjhktfq